189 related articles for article (PubMed ID: 15013039)
1. Pharmacokinetic interactions of ceftazidime, imipenem and aztreonam with amikacin in healthy volunteers.
Adamis G; Papaioannou MG; Giamarellos-Bourboulis EJ; Gargalianos P; Kosmidis J; Giamarellou H
Int J Antimicrob Agents; 2004 Feb; 23(2):144-9. PubMed ID: 15013039
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
Burgess DS; Summers KK; Hardin TC
Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia.
Bernabeu-Wittel M; Pichardo C; García-Curiel A; Pachón-Ibáñez ME; Ibáñez-Martínez J; Jiménez-Mejías ME; Pachón J
Clin Microbiol Infect; 2005 Apr; 11(4):319-25. PubMed ID: 15760430
[TBL] [Abstract][Full Text] [Related]
4. The effect of amikacin and imipenem alone and in combination against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.
Máthé A; Szabó D; Anderlik P; Rozgonyi F; Nagy K
Diagn Microbiol Infect Dis; 2007 May; 58(1):105-10. PubMed ID: 17300908
[TBL] [Abstract][Full Text] [Related]
5. Chronopharmacokinetics of imipenem in the rat.
Boulamery A; Kadra G; Simon N; Besnard T; Bruguerolle B
Chronobiol Int; 2007; 24(5):961-8. PubMed ID: 17994349
[TBL] [Abstract][Full Text] [Related]
6. Trough serum concentrations of beta-lactam antibiotics in cancer patients: inappropriateness of conventional schedules to pharmacokinetic/pharmacodynamic properties of beta-lactams.
Navas D; Caillon J; Batard E; Le Conte P; Kergueris MF; Moreau P; Potel G
Int J Antimicrob Agents; 2006 Feb; 27(2):102-7. PubMed ID: 16414248
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia.
McKindley DS; Boucher BA; Hess MM; Croce MA; Fabian TC
Pharmacotherapy; 1996; 16(5):924-31. PubMed ID: 8888088
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers.
Rasmussen BB; Larsen LS; Senderovitz T
BJOG; 2005 Nov; 112(11):1492-9. PubMed ID: 16225568
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion.
Jaruratanasirikul S; Raungsri N; Punyo J; Sriwiriyajan S
J Antimicrob Chemother; 2005 Dec; 56(6):1163-5. PubMed ID: 16234333
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.
Yang RH; Rong XZ; Hua R; Zhang T
Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacokinetics of amikacin in Greyhound and Beagle dogs.
KuKanich B; Coetzee JF
J Vet Pharmacol Ther; 2008 Apr; 31(2):102-7. PubMed ID: 18307501
[TBL] [Abstract][Full Text] [Related]
12. Postantibiotic effect of antimicrobial combinations on multidrug-resistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Kentepozidis N; Antonopoulou A; Plachouras D; Tsaganos T; Giamarellou H
Diagn Microbiol Infect Dis; 2005 Feb; 51(2):113-7. PubMed ID: 15698716
[TBL] [Abstract][Full Text] [Related]
13. Correlation of the pharmacokinetic parameters of amikacin and ceftazidime.
Panomvana D; Kiatjaroensin SA; Phiboonbanakit D
Clin Pharmacokinet; 2007; 46(10):859-66. PubMed ID: 17854235
[TBL] [Abstract][Full Text] [Related]
14. Amikacin pharmacokinetics and the effects of ambient temperature on the dosage regimen in ball pythons (Python regius).
Johnson JH; Jensen JM; Brumbaugh GW; Boothe DM
J Zoo Wildl Med; 1997 Mar; 28(1):80-8. PubMed ID: 9226620
[TBL] [Abstract][Full Text] [Related]
15. Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients.
Byl B; Baran D; Jacobs F; Herschuelz A; Thys JP
J Antimicrob Chemother; 2001 Aug; 48(2):325-7. PubMed ID: 11481316
[No Abstract] [Full Text] [Related]
16. Comparative serum bactericidal activity against Pseudomonas aeruginosa of six antipseudomonal agents.
Dan M; Zabeeda D; Poch F
Chemotherapy; 1995; 41(5):323-9. PubMed ID: 8521732
[TBL] [Abstract][Full Text] [Related]
17. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
18. [Actinomycetoma and Nocardia sp. Report of five cases treated with imipenem or imipenem plus amikacin].
Fuentes A; Arenas R; Reyes M; Fernández RF; Zacarías R
Gac Med Mex; 2006; 142(3):247-52. PubMed ID: 16875355
[TBL] [Abstract][Full Text] [Related]
19. Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants.
Wong SL; Sörgel F; Kinzig M; Goldberg MR; Kitt MM; Barriere SL
J Clin Pharmacol; 2009 Jul; 49(7):816-23. PubMed ID: 19443680
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model.
McGrath BJ; Bailey EM; Lamp KC; Rybak MJ
Antimicrob Agents Chemother; 1992 Dec; 36(12):2741-6. PubMed ID: 1482142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
